FDA Updates Lumateperone Label With Relapse-Prevention Data - Quiz - MDSpire

FDA Updates Lumateperone Label With Relapse-Prevention Data

Label update incorporates randomized withdrawal trial findings showing delayed time to relapse and consistent safety profile in schizophrenia

  • By

  • Kathryn Wighton

  • April 29, 2026

  • 2 min

Share

Original Source(s)

FDA Updates Lumateperone Label With Relapse-Prevention Data

  • by Kathryn Wighton

  • April 29, 2026

Related Content

A systematic review of internet addiction in hospitalized adolescents: proposing a hospital-adapted moderated dual mediation model of emotional dysregulation and social compensation

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Using the NASSS–Complexity Assessment Tool to Evaluate the Implementation of “Cadê O Kauê?”: Chat-Story Intervention for Youth Participation in Mental Health Promotion in Brazil